Atopic dermatitis is a common inflammatory skin disease with a strong heritable component. Pathogenetic models consider keratinocyte differentiation defects and immune alterations as scaffolds 1 , and recent data indicate a role for autoreactivity in at least a subgroup of patients 2 . FLG (encoding filaggrin) has been identified as a major locus causing skin barrier deficiency 3 . To better define risk variants and identify additional susceptibility loci, we densely genotyped 2,425 German individuals with atopic dermatitis (cases) and 5,449 controls using the Immunochip array followed by replication in 7,196 cases and 15,480 controls from Germany, Ireland, Japan and China. We identified four new susceptibility loci for atopic dermatitis and replicated previous associations. This brings the number of atopic dermatitis risk loci reported in individuals of European ancestry to 11. We estimate that these susceptibility loci together account for 14.4% of the heritability for atopic dermatitis.
Manhattan plot of the Immunochip association statistics highlighting atopic dermatitis susceptibility loci. The red horizontal line indicates a genome-wide significance threshold of P = 5 × 10 −8 , and the black horizontal line indicates the threshold for followup genotyping of the most strongly associated SNPs (n = 34) with P Immunochip <10 −4 from each associated locus in an independent case-control collection (supplementary table 1b). SNPs within five known and four newly associated loci (depicted in blue) (table 1) reached the GWS threshold for association with atopic dermatitis in the combined analysis of the Immunochip discovery and replication stages (supplementary table 1a-c). 
e t t e r s
Analysis of linkage disequilibrium (LD) patterns showed that rs72702813 does not tag the psoriasis deletion (D′ = 1.0, r 2 = 0.09 with proxy SNP rs4112788 (ref. 14) ) but is in moderate LD (D′ = 0.63, r 2 = 0.38) with the known FLG mutation c.2282del4 (Supplementary Table 3 ). After conditioning on FLG mutations (p.Arg501X, c.2282del4, p.Arg2447X and p.Ser3247X), rs72702813 no longer showed association (P cond = 0.94, odds ratio (OR) = 0.99, 95% confidence interval (CI) 0.77-1.28).
Another locus at CLEC16A (16p13.13), which was not previously known to be associated with atopic dermatitis, attained GWS (P rs2041733 = 1.00 × 10 −11 , OR = 1.26, 95% CI 1.18-1.35) ( Table 1) . For the two remaining established loci, we observed a significant signal for OVOL1 (11q13.1) (P rs11820062 = 3.60 × 10 −6 ) but not ACTL9 (19p13.2) (P rs2967682 = 0.18) (Supplementary Fig. 1 ), which is sparsely covered on the Immunochip (r 2 = 0.15 between rs2967682 and the lead SNP rs2164983 from a previous GWAS 6 ). Furthermore, we replicated the association at the TNFRSF6B (20q13.33) locus (P rs909341 = 7.73 × 10 −10 , OR = 0.76, 95% CI 0.70-0.83), which was previously reported in a Chinese population, with GWS in Europeans. This gene encodes a soluble decoy receptor (DcR3) that acts as an immunomodulator (for example, in support of T helper type 2 (T H 2) cell polarization, which is a hallmark feature of atopic dermatitis) 16 . DcR3 is overexpressed in inflamed epithelia, and increased serum concentrations of this protein have been reported in autoimmune and inflammatory diseases 17, 18 . In line with this, we observed a slight overexpression in serum from patients with atopic dermatitis (P Fisher = 0.00049; Supplementary  Fig. 2 ). However, immunohistochemistry showed strong epidermal staining with no clear differences between atopic dermatitis lesional and healthy skin (Supplementary Fig. 3 ). No proxy SNPs (r 2 > 0.5) were available for the 5q22.1 locus identified in the Chinese population (TMEM232-SLC25A46). For the recently reported loci in a Japanese population, we observed significant associations at 2q12.1 (IL1RL1-IL18R1-IL18RAP, P rs13015714 = 2.81 × 10 −5 , OR = 1.18, 95% CI 1.09-1.27), 6p21.3 (GPSM3, P rs176095 = 2.53 × 10 −5 , OR = 0.83, 95% CI 0.76-0.90) and 7p22 (CARD11, P rs6978200 = 2.34 × 10 −3 , OR = 1.12, 95% CI 1.04-1.20, r 2 = 0.58 with the reported SNP rs4722404). We found no association for 3p21.33 (GLB1, P rs35480293 = 0.80, r 2 = 0.92 with the reported SNP rs6780220) or 10q21.2 (ZNF365, P rs10995251 = 0.08). The 3q13.2 (CCDC80) and 20q13 (CYP24A1-PFDN4) loci have more limited coverage on the Immunochip array.
To identify additional susceptibility loci, we analyzed the most strongly associated SNPs (n = 34) with P Immunochip < 10 −4 after the clumping procedure from each associated locus in an independent set of 794 German cases and 3,338 controls (Supplementary Table 1c ). In a meta-analysis (P Immunochip+Repl ) of the discovery (P Immunochip ) and replication (P Repl ) stages (Supplementary Table 1a -c), SNPs within six distinct regions met the GWS threshold (Table 1) . Again, we observed association at 16p13.13 for SNP rs2041733 in CLEC16A (P Immunochip+Repl = 3.44 × 10 −15 , OR Immunochip+Repl = 1.23, 95% CI 1.17-1.29). CLEC16A encodes a sugar-binding, C-type lectin expressed on B lymphocytes, natural killer cells and dendritic cells that is functionally active through an immunoreceptor tyrosine-based activation motif (ITAM) 19 . Several SNPs in CLEC16A have been associated with immune-mediated diseases such as multiple sclerosis, type 1 diabetes 20, 21 and alopecia areata 22 , a frequent comorbidity of atopic dermatitis.
We found a significant association at 11p13 for rs12295535 in PRR5L (P Immunochip+Repl = 7.96 × 10 −13 , OR Immunochip+Repl = 1.68, 95% CI 1.46-1.93), which encodes a protein that promotes apoptosis 23 . 27 and celiac disease 28 . Stepwise conditional regression identified evidence for three independent signals (rs759382 in SLC9A4; rs3771180 in IL1RL1, which was previously implicated in asthma 29 ; and rs10185897 in IL1RL1-IL18R1) with P < 5 × 10 −4 and showed that the recently reported variant rs13015714 (ref. 12) tags rs759382 (Supplementary Table 5 ).
We found additional significant associations for rs16948048 at 17q21.32 (ZNF652, P Immunochip+Repl = 2.92 × 10 −9 , OR Immunochip+Repl = 1.17, 95% CI 1.11-1.23) and rs17389644 at 4q27 (IL2-IL21, P Immunochip+Repl = 1.39 × 10 −8 , OR Immunochip+Repl = 1.19, 95% CI 1.12-1.26). ZNF652 encodes a transcriptional repressor that is implicated in epithelial cancers 30 . IL-2 has pleiotropic immunoregulatory functions, in particular control of the proliferation and survival of regulatory T cells 31 . The IL2 locus is tightly linked with IL21, and variants in IL2, its high-affinity receptor IL2RA and IL21 have been associated with multiple immune-mediated diseases. None of the SNPs chosen from the major histocompatibility complex replicated. Regional association plots of the nine atopic dermatitis susceptibility loci with GWS in Europeans are shown in Supplementary Figure 4 . The four newly associated loci collectively increase the explained heritability from 9% to 14.4% (Supplementary Table 6 ).
To further determine the impact of the new susceptibility loci identified in Europeans on atopic dermatitis risk in diverse populations, we tested them for association in 2,397 adult Japanese cases and 7,937 controls from a recent GWAS 12 and 2,848 adult Chinese cases and 2,944 controls (Supplementary Table 1d ). In the Japanese study population, all new loci except IL2-IL21 passed the Bonferroni-corrected significance threshold (P < 0.05/6 = 0.008) for replication, and in the Chinese study population, two loci (CLEC16A and TNFRSF6B) passed this threshold ( Table 2 and  Supplementary Table 4) . Thus, CLEC16A and TNFRSF6B seem to be relevant to atopic dermatitis in both these European and Asian populations, whereas results for the other loci might reflect phenotypic and ancestry differences between the studies.
Because atopic dermatitis is often coexpressed with asthma, to enhance the interpretation of our findings, we analyzed Immunochip data from an independent set of 733 German cases with asthma 32 and 2,503 controls for atopic dermatitis, asthma, atopic dermatitis without asthma and asthma without atopic dermatitis (Online Methods). We found that all of the newly identified susceptibility loci associated primarily with atopic dermatitis (Supplementary Table 7) .
For the nine loci associated at GWS (Table 1) , we identified seven coding SNPs highly correlated (r 2 > 0.9 in 1000 Genomes Project European samples) with the lead SNPs (Supplementary Table 8 ). However, these nonsynonymous SNPs are predicted in silico to have a nondamaging effect on protein products.
Analysis of whole-blood samples from 740 German control individuals identified evidence for correlation between the expression of IL1RL1, ARAP3, MAP3K11 and STMN3 and SNP alleles in high LD (r 2 > 0.95) with the most strongly associated SNPs listed in Table 1 (Supplementary Table 9 ). Examination of expression levels in skin biopsies from 64 healthy controls run on HU133 Plus 2.0 arrays 33 yielded no evidence for cis-regulatory effects ( Supplementary  Table 10 ). However, a regulatory effect in another physiological state (for example, atopic dermatitis) cannot be ruled out.
We next looked for statistical interactions (allelic-by-allelic epistasis) between lead SNPs of each locus shown in Table 1 (Supplementary  Table 11 ). One SNP pair (rs848 (IL13) and rs2041733 (CLEC16A)) showed evidence for interaction (P = 5.41 × 10 −4 ) after Bonferroni correction (P < 0.05/36 = 1.39 × 10 −3 ). rs848 is in tight LD with the functional IL13 variant rs20541 (r 2 = 0.979), which affects the activation of the signal transducer and activator of transcription 6 (STAT6) signaling pathway 34 . CLEC16A is thought to act through its ITAM, the ligation of which modulates JAK-STAT signaling 35 . Thus, the observed interactions reflect potential functional links, which need further investigation.
In summary, our dense genotyping approach using the Immunochip array identified four new atopic dermatitis risk loci in Europeans (Table 1) , adding 5.4% to the estimate of explained atopic dermatitis heritability and bringing the total to 14.4% heritability explained by currently reported susceptibility loci. Our results expand the catalog of genetic loci implicated in atopic dermatitis and provide evidence for a substantial contribution of loci shared with other immunemediated diseases. Fig. 1 ). Chr., chromosome of the marker; genomic positions were retrieved from NCBI dbSNP build v130 (genome build hg18); A1, minor allele; A2, major allele; key gene(s), candidate gene(s) in the region. P values and ORs were calculated with respect to the minor allele. rs72702813 failed replication genotyping in the Japanese study due to technical reasons.
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METhods
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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We thank all individuals with atopic dermatitis, their families, control individuals and clinicians for their participation. We thank T. Table 1a ) were recruited from tertiary dermatology and pediatrics clinics based at four centers (Technische Universität Munich, as part of the Gene-Environment Association (GENEVA) study, the University of Kiel, the University of Bonn and University Children's Hospital, Charité Universitätsmedizin Berlin, as part of the Genetic Studies in Nuclear Families with Atopic Dermatitis (GENUFAD) study). Atopic dermatitis was diagnosed on the basis of a skin examination performed by experienced dermatologists and pediatricians according to standard criteria, which included the presence of chronic or chronically relapsing pruritic dermatitis with the typical morphology and distribution 36 . A total of 2,461 German controls were obtained from the PopGen biorepository 37 . A total of 1,545 cases with atopic dermatitis and all 2,461 controls from PopGen were genotyped at the Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, and 880 cases with atopic dermatitis were genotyped at the Max-Delbrück-Centrum (MDC) for Molecular Medicine (Berlin-Buch, Germany). Nine-hundred seventy-nine German controls were selected as part of an independent population-based sample from the general population living in the region of Augsburg (Cooperative Heath Research in the Region of Augsburg (KORA)), southern Germany 38 , and were genotyped at the Helmholtz Center in Munich. Three hundred and two control individuals were of south German ancestry and were part of the control population from Munich recruited from the Bavarian Red Cross; 208 control individuals were recruited from the Charité-Universitätsmedizin Berlin. These samples were genotyped at the University of Pittsburgh Genomics and Proteomics Core Laboratories (R.H.D., principal investigator). The Bonn controls (n = 1,499) were recruited from the population-based epidemiological Heinz Nixdorf Recall study 39 and genotyped at the Life and Brain Center at the University Clinic in Bonn. Of the cases with atopic dermatitis used for the screen with available phenotype information, 33.1% and 31.0% (Supplementary Table 1a) suffered from comorbid asthma.
Study subjects. Immunochip data. All German cases with atopic dermatitis (Supplementary
For in silico analysis of the selected SNPs for asthma, Immunochip data from 733 German cases with asthma from the MAGICS and German ISAAC studies 9 , as well as 2,503 controls from PopGen, were used. Table 1b) , we used 794 cases recruited at tertiary dermatology clinics in Munich, Bonn, Kiel and Hannover (Technische Universität Munich, as part of the GENEVA study, the University of Bonn, the University of Kiel and Medizinische Hochschule of Hannover). A total of 2,412 German control individuals were selected as part of the EMIL study, an independent population-based sample from the general population living in Leukirch, southern Germany 40 . A total of 926 German control individuals were selected as part of an independent population-based sample from the general population living in the region of Augsburg (KORA), southern Germany 38 , and were genotyped at the Helmholtz Center in Munich. The Irish case-control collection consisted of 1,157 unrelated children of self-reported Irish ancestry with moderate-to-severe atopic dermatitis recruited from the tertiary referral pediatric dermatology clinic based at Our Lady's Children's Hospital, Dublin (Supplementary Table 1c) . A total of 1,261 unselected control samples were obtained from the population-based Trinity Biobank Control samples.
Replication data. For follow-up genotyping (Supplementary
For further replication, a total of 2,397 Japanese cases and 7,937 Japanese controls were analyzed (Supplementary Written, informed consent was obtained from all study participants, and the institutional ethical review committees of the participating centers approved all protocols.
Immunochip genotyping. DNA samples were genotyped using the Immunochip, which is an Illumina iSelect HD custom genotyping array. The Immunochip is a BeadChip developed for highly multiplexed SNP genotyping of complex DNA. Data were analyzed using Illumina's GenomeStudio Genotyping Module. The NCBI build 36 (hg18) map was used (Illumina manifest file Immuno_BeadChip_11419691_B.bpm), and normalized probe intensities were extracted for all samples that passed standard laboratory quality-control thresholds.
Immunochip genotype calling and quality control. Genotype calling was performed with the GenomeStudio GenTrain 2.0 algorithm (Illumina's GenomeStudio data analysis software) and the custom generated cluster file of Trynka et al. (based on an initial clustering of 2,000 UK samples and subsequent manual readjustment of cluster positions) 13 .
SNPs that had >5% missing data, a minor allele frequency <1% or deviated from Hardy-Weinberg equilibrium (exact P < 10 −4 in controls) per sample study were excluded using PLINK software version 1.07 (ref. 42 ). Sample quality control measures included sample call rate, overall heterozygosity, relatedness testing and other metrics (Supplementary Figs. 5-7) . The remaining 2,425 cases with atopic dermatitis and 5,449 controls were tested for population stratification using the principal components stratification method as implemented in EIGENSTRAT 43 . Principal component analysis revealed no population stratification in the remaining samples; no population outliers were detected. A total of 128,830 polymorphic SNPs were available for analysis. A quantile-quantile plot of the full association analysis showed a marked excess of significant associations in the tail of the distribution (Supplementary Fig. 8a ), which was due primarily to hundreds of highly significant association signals from a few associated (fine-mapped) regions. A quantile-quantile plot using 2,714 'null' SNPs not associated with autoimmune disease (bipolar disease-associated SNPs) 13 is shown as negative control, and the inflation factor inferred from this showed only modest inflation (λ = 1.01; Supplementary Fig. 8b ).
Replication genotyping. For replication genotyping, we selected the most strongly associated SNP (n = 34) with P < 10 −4 from each associated locus by means of PLINK's clumping procedure (using default settings: P 1 < 0.0001, P 2 < 0.01, r 2 ≥ 0.5, kb = 250) representing 23 loci (see also Supplementary Table 4) . Follow-up replication genotyping in the German study population was carried out using our Sequenom iPlex platform from Sequenom and TaqMan technology from Applied Biosystems. Replication typing in the Irish case-control collection was done using TaqMan technology from Applied Biosystems. Quality control was done for each country population separately. Individuals with >8% missing data were removed. SNPs that had >3% missing data or deviated from Hardy-Weinberg equilibrium (exact P < 0.01 in controls) per sample population were excluded. P values for allele-based tests of phenotypic association for each single replication population were calculated using R 2.14.2 (ref. 44 ). PLINK's meta-analysis function was used to obtain P values for the replication data set (P Repl ) (Supplementary Table 1b,c) and the combined discovery-replication data set (P Immunochip+Repl ) (Supplementary  Table 1a-c) . We used the commonly accepted threshold of P = 5 × 10 −8 for joint P values to define statistical significance.
The Japanese replication set was typed using multiplex PCR-based Invader assay (Third Wave Technologies). Genotyping in the Chinese replication cohort was carried out using Sequenom technology.
Annotation of association boundaries. LD regions (association boundaries) around focal SNPs were defined by extending in both directions a distance of 0.1 centimorgans (cM) or until another SNP with P < 10 −5 was reached, in which case the process was repeated from this SNP. For each locus, candidate genes within regions are listed in columns labeled 'key gene(s)' in Tables 1  and 2 and are listed in more detail in Supplementary Table 4. Annotation of associations to other phenotypes. Overlaps with other phenotypes were annotated with the National Human Genome Research Institute npg (NHGRI) GWAS catalog 45 (www.genome.gov/gwastudies, accessed December 19, 2012) . All known associations with P < 5 × 10 −8 to any disease or primary phenotype were included. For each atopic dermatitis susceptibility locus with association boundaries defined in Table 1 , we annotated all phenotypes that had at least one associated SNP within the region. We also checked whether the hit SNP in the NHGRI GWAS catalog was the same as, or in high LD with (r 2 > 0.9), the atopic dermatitis hit SNP.
Stepwise conditional logistic regression and joint analysis. Multiple associated SNPs were selected through a stepwise selection procedure using GCTA (Genome-wide Complex Trait Analysis) 46 using SNP markers at 2q12.1 and a threshold P value of 5 × 10 −4 to declare evidence for independently associated SNPs (-massoc-p 5e-4) (Supplementary Table 5a) .
Expression quantitative trait loci look up. We analyzed gene expression data measured previously in whole blood (fasting conditions) and skin specimens. Table 9 ). For analysis of skin, we used Affymetrix HU133 Plus 2.0 arrays data from 57 healthy individuals 33 (Supplementary Table 10 ).
Statistical interaction analysis.
To look for interactions between associated loci, we considered all distinct pairs (n = 36) of the nine lead SNPs listed in Table 1 (see Supplementary Table 11 ).
Immunohistochemistry. Immunohistochemical staining of paraffin-embedded tissue of eight biopsies taken from lesions of patients with atopic dermatitis compared to eight healthy sex-and age-matched control persons was done by using monoclonal mouse anti-DcR3 (see Supplementary Fig. 3 ).
Serum measurements. Analysis of DcR3 serum concentrations was done using the DuoSet ELISA development system from R&D Systems (Wiesbaden, Germany) according to the manufacturer's instructions.
